Zevra Q2 2026 revenue rises 53% to $39.7 million; net income falls from prior year
Zevra Therapeutics reported second-quarter 2026 revenue of $39.7 million, up 53% from $25.9 million a year earlier, with $30.2 million from MIPLYFFA. Net income fell to $8.8 million, or $0.14 per diluted share, from $74.7 million, or $1.21 per diluted share, in Q2 2025, which included a $148.3 million gain on the sale of a priority review voucher. Cash, cash equivalents and investments were $260.2 million as of June 30, 2026.
Key points
- Total net revenue of $39.7 million for Q2 2026, up $13.8 million from $25.9 million in Q2 2025
- MIPLYFFA net revenue of $30.2 million in Q2 2026; OLPRUVA net revenue of $0.2 million
- Net income of $8.8 million ($0.14 per diluted share) vs. $74.7 million ($1.21) in Q2 2025, which included a $148.3 million priority review voucher sale gain
- Cash, cash equivalents and investments of $260.2 million as of June 30, 2026
The filing
Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 05, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.